This satiety is particularly beneficial for those on semaglutide, as the medication suppresses appetite
TAM: F (1,21) = 1.843, p = 0.1890
McCall WD, Tanner KD, Levine JD
The dataset was partitioned randomly into training (70% of the sample) and held out test (30%) sets, with the test set being used to assess model performance
One notable study reported that participants who took semaglutide experienced an average weight loss of 14.9% from their baseline weight over a 68-week period, compared to 2.4% in the placebo group
The results demonstrate that DSIP significantly accelerates the recovery of motor function, although its effect on brain infarct volume did not reach statistical significance